Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INF037
MIFTS: 53

Inflammatory Bowel Disease

Categories: Gastrointestinal diseases, Genetic diseases, Rare diseases, Bone diseases, Blood diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Inflammatory Bowel Disease

About this section

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 37 6 3 15
Inflammatory Bowel Diseases 55 44 73
Bowel Disease, Inflammatory 40

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Bone diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050589
MeSH 44 D015212
NCIt 50 C3138
KEGG 37 H01227
UMLS 73 C0021390
Sources

Summaries for Inflammatory Bowel Disease

About this section
CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 5 and inflammatory bowel disease 20. An important gene associated with Inflammatory Bowel Disease is NRON (Non-Protein Coding RNA, Repressor Of NFAT
Mechanistic studies showed that LRRK2 was a potent negative regulator of the transcription factor NFAT and was a component of a complex that included the large noncoding RNA NRON.
Dysfunction Pattern: Regulation [down-regulated]), and among its related pathways/superpathways are Antigen processing and presentation and Cytokine-cytokine receptor interaction. The drugs Infliximab and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include all parts of digestive tract, colon and bone.

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

Wikipedia : 76 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Sources

Related Diseases for Inflammatory Bowel Disease

About this section

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 28 Inflammatory Bowel Disease 25

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 365)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 5 35.9 IBD5 IL23R NOD2
2 inflammatory bowel disease 20 35.6 IBD20 NOD2
3 inflammatory bowel disease 2 35.6 IBD2 NOD2
4 inflammatory bowel disease 8 35.5 IBD8 NOD2
5 inflammatory bowel disease 7 35.5 IBD7 NOD2
6 inflammatory bowel disease 9 35.4 IBD9 NOD2
7 inflammatory bowel disease 4 35.3 IBD4 NOD2
8 inflammatory bowel disease 3 35.1 IBD3 NOD2
9 inflammatory bowel disease 6 34.6 IBD6 NOD2
10 inflammatory bowel disease 1 12.6
11 inflammatory bowel disease 25, autosomal recessive 12.5
12 inflammatory bowel disease 19 12.5
13 inflammatory bowel disease 10 12.5
14 inflammatory bowel disease 28, autosomal recessive 12.4
15 inflammatory bowel disease 17 12.4
16 inflammatory bowel disease 13 12.4
17 inflammatory bowel disease 14 12.4
18 inflammatory bowel disease 16 12.4
19 inflammatory bowel disease 18 12.4
20 inflammatory bowel disease 11 12.4
21 inflammatory bowel disease 12 12.4
22 inflammatory bowel disease 15 12.4
23 inflammatory bowel disease 21 12.4
24 inflammatory bowel disease 22 12.4
25 inflammatory bowel disease 23 12.4
26 inflammatory bowel disease 24 12.4
27 inflammatory bowel disease 26 12.4
28 inflammatory bowel disease 27 12.4
29 inflammatory bowel disease 28 12.4
30 inflammatory bowel disease 25 12.3
31 ulcerative colitis 11.9
32 gastrointestinal defects and immunodeficiency syndrome 11.7
33 crohn's disease 11.5
34 cholangitis, primary sclerosing 11.4
35 irritable bowel syndrome 11.4
36 colitis 11.4
37 spondyloarthropathy 1 11.4
38 collagenous colitis 11.3
39 ileitis 11.3
40 glycogen storage disease ib 11.3
41 corticosteroid-sensitive aseptic abscesses 11.3
42 proctitis 11.2
43 chronic recurrent multifocal osteomyelitis 11.2
44 lymphoproliferative syndrome, x-linked, 2 11.2
45 chronic pain 11.2
46 immunodeficiency, common variable, 11 11.1
47 diarrhea 6 11.0
48 immunodeficiency, common variable, 8, with autoimmunity 11.0
49 ileocolitis 11.0
50 cutaneous photosensitivity and colitis, lethal 10.9

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease
Sources

Symptoms & Phenotypes for Inflammatory Bowel Disease

About this section
Sources

Drugs & Therapeutics for Inflammatory Bowel Disease

About this section

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 526)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
2
Clarithromycin Approved Phase 4,Phase 3,Not Applicable 81103-11-9 84029
3
Clofazimine Approved, Investigational Phase 4,Phase 3 2030-63-9 2794
4
Rifabutin Approved, Investigational Phase 4,Phase 3 72559-06-9 6323490
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
7
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
8
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
11
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
12
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
13
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 122320-73-4 77999
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
15
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
16 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 943609-66-3
17
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
18
Bupropion Approved Phase 4,Phase 2,Phase 3 34841-39-9, 34911-55-2 444
19
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
20
Menthol Approved Phase 4,Phase 1,Phase 2,Not Applicable 2216-51-5 16666
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
22
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
23
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
24
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
25
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
26
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
27
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
28
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
29
Ibuprofen Approved Phase 4 15687-27-1 3672
30
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
31
Azithromycin Approved Phase 4 83905-01-5 55185 447043
32
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
33
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 63006 5281004
34
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 189261-10-7
35
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
36
Thioguanine Approved Phase 4,Phase 1 154-42-7 2723601
37
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
38
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
39
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
40
Nicotine Approved Phase 4,Phase 3 54-11-5 942 89594
41
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 441141 14969
42
Copper Approved, Investigational Phase 4 7440-50-8 27099
43
Zinc Approved, Investigational Phase 4 7440-66-6 23994
44
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
45
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
46
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
47
Ondansetron Approved Phase 4,Phase 3 99614-02-5 4595
48
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
49
Dextromethorphan Approved Phase 4,Phase 1 125-71-3 5360696 5362449
50
Losartan Approved Phase 4 114798-26-4 3961

Interventional clinical trials:

(show top 50) (show all 1969)
# Name Status NCT ID Phase Drugs
1 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
2 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
3 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
4 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
5 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
6 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
7 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
8 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
9 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
10 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
11 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
12 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4 Infliximab
13 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4 VSL#3
14 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
15 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
16 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
17 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
18 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
19 A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis Unknown status NCT02425852 Phase 4 Azathioprine;Infliximab;Prednisolone;Hydrocortisone
20 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
21 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
22 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
23 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
24 Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
25 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4 bupropion-SR
26 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
27 Low Volume Colon Preparation for IBD Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
28 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
29 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
30 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
31 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
32 Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Completed NCT02946203 Phase 4
33 Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
34 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
35 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
36 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
37 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
38 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Completed NCT02010762 Phase 4 Vitamin D;Placebo
39 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
40 Pneumococcal Vaccination of Crohn Patients Completed NCT01947010 Phase 4
41 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
42 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
43 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
44 Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease Completed NCT01215890 Phase 4 risedronate;placebo
45 NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery Completed NCT01056913 Phase 4
46 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
47 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Completed NCT02148718 Phase 4
48 Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
49 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
50 Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease Completed NCT02349594 Phase 4 Omegaven 10%;Intralipid 20%

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: inflammatory bowel diseases

Sources

Genetic Tests for Inflammatory Bowel Disease

About this section
Sources

Anatomical Context for Inflammatory Bowel Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Inflammatory Bowel Disease:

19
All Parts Of Digestive Tract

MalaCards organs/tissues related to Inflammatory Bowel Disease:

41
Colon, Bone, Testes, T Cells, Liver, Small Intestine, Endothelial
Sources

Publications for Inflammatory Bowel Disease

About this section

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 3016)
# Title Authors Year
1
Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges. ( 29430322 )
2018
2
Decreased risk for microscopic colitis and inflammatory bowel disease among patients with reflux disease. ( 29603881 )
2018
3
Inflammatory bowel disease and acute anterior uveitis, but not psoriasis are associated with disease duration in Axial SpA: results from the (Be)Giant and ASPECT cohort. ( 29740978 )
2018
4
Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis. ( 29392650 )
2018
5
The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies. ( 29956079 )
2018
6
The pre-treatment characteristics and evaluation of the effects of recombinant human growth hormone therapy in children with growth hormone deficiency and celiac disease or inflammatory bowel disease. ( 29736148 )
2018
7
The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. ( 29431201 )
2018
8
Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity. ( 29438136 )
2018
9
The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )
2018
10
How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. ( 29957083 )
2018
11
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? ( 29432749 )
2018
12
Prevalence of inflammatory bowel disease in alcoholic, non-alcoholic and autoimmune pancreatitis. ( 29734447 )
2018
13
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. ( 29430672 )
2018
14
Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )
2018
15
De-escalation of Therapy in Inflammatory Bowel Disease. ( 29961926 )
2018
16
Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. ( 29862092 )
2018
17
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )
2018
18
Reply: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29314243 )
2018
19
Increased risk for inflammatory bowel disease in congenital hypothyroidism supports the existence of a shared susceptibility factor. ( 29977049 )
2018
20
Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. ( 29457211 )
2018
21
A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. ( 29968143 )
2018
22
Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis. ( 29440920 )
2018
23
Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population-Based Cohort Study. ( 29538289 )
2018
24
Vitamin D: a brief overview of its importance and role in inflammatory bowel disease. ( 29971262 )
2018
25
Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. ( 29424814 )
2018
26
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
27
Low childhood high density lipoprotein cholesterol levels and subsequent risk for chronic inflammatory bowel disease. ( 29426615 )
2018
28
High level of IgG4 as a biomarker for a new subset of inflammatory bowel disease. ( 29968792 )
2018
29
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. ( 29808485 )
2018
30
Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. ( 29430323 )
2018
31
How ameliorate the adherence in patients with inflammatory bowel disease? ( 29969048 )
2018
32
TTC7A mutation must be considered in patients with repeated intestinal atresia associated with early inflammatory bowel disease: Two new case reports and a literature review. ( 29921470 )
2018
33
Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. ( 29617820 )
2018
34
Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. ( 29437914 )
2018
35
Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. ( 29972674 )
2018
36
Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD. ( 29931102 )
2018
37
Similar subclinical enthesitis in celiac and inflammatory bowel diseases by ultrasound suggests a gut enthesis axis independent of spondyloarthropathy spectrum. ( 29741671 )
2018
38
Toll-like Receptors and Inflammatory Bowel Disease. ( 29441063 )
2018
39
Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. ( 29440933 )
2018
40
Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. ( 29357084 )
2018
41
Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease. ( 29971936 )
2018
42
Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. ( 29955835 )
2018
43
Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease. ( 29484893 )
2018
44
Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. ( 29852184 )
2018
45
An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. ( 29436901 )
2018
46
Acquired cutis laxa associated with inflammatory bowel disease, inflammatory arthritis and IgA nephropathy. ( 29536978 )
2018
47
Therapeutic Effect of <i>Amomum villosum</i> on Inflammatory Bowel Disease in Rats. ( 29973876 )
2018
48
Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease. ( 29973488 )
2018
49
Immunization Coverage in Children with Inflammatory Bowel Disease. ( 29429027 )
2018
50
Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease. ( 28872665 )
2018